Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Coverage Initiated by Analysts at Janney Montgomery Scott

Janney Montgomery Scott began coverage on shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in a research note issued to investors on Friday, July 14th, MarketBeat reports. The firm set a “neutral” rating and a $47.00 price target on the specialty pharmaceutical company’s stock. Janney Montgomery Scott’s price target indicates a potential upside of 13.53% from the company’s previous close.

Other equities research analysts have also recently issued reports about the company. Cantor Fitzgerald lifted their price objective on Supernus Pharmaceuticals from $25.00 to $27.00 and gave the company an “overweight” rating in a research note on Thursday, May 11th. Jefferies Group LLC lifted their price objective on Supernus Pharmaceuticals from $35.00 to $45.00 and gave the company a “buy” rating in a research note on Wednesday, May 31st. Piper Jaffray Companies raised Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $30.00 to $44.00 in a research note on Thursday, June 1st. Cowen and Company lifted their price objective on Supernus Pharmaceuticals from $31.00 to $34.00 and gave the company an “outperform” rating in a research note on Thursday, May 11th. Finally, Stifel Nicolaus lifted their price objective on Supernus Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, April 3rd. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Supernus Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $48.43.

Supernus Pharmaceuticals (NASDAQ:SUPN) opened at 41.40 on Friday. The stock’s 50 day moving average price is $42.47 and its 200-day moving average price is $34.12. The company has a market cap of $2.10 billion, a P/E ratio of 20.89 and a beta of 1.31. Supernus Pharmaceuticals has a 52-week low of $17.25 and a 52-week high of $44.95.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.24 by $0.08. Supernus Pharmaceuticals had a return on equity of 30.73% and a net margin of 41.10%. The business had revenue of $75.83 million during the quarter, compared to analysts’ expectations of $68.54 million. On average, equities analysts predict that Supernus Pharmaceuticals will post $1.04 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The original version of this report can be viewed at https://www.com-unik.info/2017/08/12/supernus-pharmaceuticals-inc-nasdaqsupn-coverage-initiated-by-analysts-at-janney-montgomery-scott-updated-updated-updated.html.

In related news, VP Padmanabh P. Bhatt sold 5,500 shares of the business’s stock in a transaction on Thursday, May 25th. The stock was sold at an average price of $34.90, for a total transaction of $191,950.00. Following the completion of the transaction, the vice president now directly owns 43,887 shares of the company’s stock, valued at approximately $1,531,656.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Padmanabh P. Bhatt sold 2,556 shares of the business’s stock in a transaction on Friday, June 23rd. The stock was sold at an average price of $44.90, for a total value of $114,764.40. Following the transaction, the vice president now directly owns 24,944 shares of the company’s stock, valued at $1,119,985.60. The disclosure for this sale can be found here. Insiders have sold a total of 24,291 shares of company stock valued at $962,766 over the last three months. 6.70% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Rice Hall James & Associates LLC boosted its position in Supernus Pharmaceuticals by 1.1% in the first quarter. Rice Hall James & Associates LLC now owns 1,093,402 shares of the specialty pharmaceutical company’s stock valued at $34,223,000 after buying an additional 11,662 shares in the last quarter. Capital Impact Advisors LLC acquired a new position in Supernus Pharmaceuticals during the first quarter valued at about $1,263,000. Legato Capital Management LLC boosted its position in Supernus Pharmaceuticals by 3,030.0% in the first quarter. Legato Capital Management LLC now owns 67,577 shares of the specialty pharmaceutical company’s stock valued at $2,159,000 after buying an additional 65,418 shares in the last quarter. Louisiana State Employees Retirement System boosted its position in Supernus Pharmaceuticals by 2.5% in the first quarter. Louisiana State Employees Retirement System now owns 20,400 shares of the specialty pharmaceutical company’s stock valued at $639,000 after buying an additional 500 shares in the last quarter. Finally, Juncture Wealth Strategies LLC boosted its position in Supernus Pharmaceuticals by 0.8% in the first quarter. Juncture Wealth Strategies LLC now owns 51,459 shares of the specialty pharmaceutical company’s stock valued at $1,611,000 after buying an additional 433 shares in the last quarter. 94.39% of the stock is owned by institutional investors and hedge funds.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

What are top analysts saying about Supernus Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Supernus Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit